In this study, Imani et al. investigate whether a new proprietary herbal formulation, HF1, can inhibit expression of immune suppressor protein PD-L1. PD-L1 is a transmembrane protein that can be expressed by cancer cells to assist in their ability to avoid attacks from the immune system. Work from this study demonstrates that HF1 treatment can reduce expression of PD-L1 in cultured cancer cells, implicating HF1 as a potential new cancer therapy.

Here, recognizing the significant growth of electronic cigarettes in recent years, the authors sought to test a hypothesis that three main components of the liquid solutions used in e-cigarettes might affect lung cancer cell viability. In a study performed by exposing A549 cells, human lung cancer cells, to different types of smoke extracts, the authors found that increasing levels of nicotine resulted in improve lung cancer cell viability up until the toxicity of nicotine resulted in cell death. They conclude that these results suggest that contrary to conventional thought e-cigarettes may be more dangerous than tobacco cigarettes in certain contexts.

With disruption of DNA repair pathways pertinent to the timeline of cancer, thorough evaluation of mutations relevant to DNA repair proteins is crucial within cancer research. One such mutation includes S815L PMS2 - a mutation that results in significant decrease of DNA repair function by PMS2 protein. While mutation of PMS2 is associated with significantly increased colorectal and endometrial cancer risk, much work is left to do to establish the functional effects of the S815L PMS2 mutation in ovarian cancer progression. In this article, researchers contribute to this essential area of research by uncovering the tumor-progressive effects of the S815L PMS2 mutation in the context of ovarian cancer cell lines.

Pancreatic cancer is one of the deadliest cancers, with a 10% 5-year survival rate. The authors studied various dosages of TPEN and zinc in combination with Chloroquine and Gemcitabine as treatments to reduce cell proliferation. Results showed that when combined with Chloroquine and Gemcitabine, zinc and TPEN both significantly lowered cell proliferation compared to Gemcitabine, suggesting a synergistic effect that resulted in a more cytotoxic treatment. Further research and clinical trials on this topic are needed to determine whether this could be a viable treatment for pancreatic cancer.

Luteolin (3′,4′,5,7-tetrahydroxyflavone) is a flavonoid that occurs in fruits, vegetables, and herbs. Research suggests that luteolin is effective against various forms of cancer by triggering apoptosis pathways. This experiment analyzes the effects of luteolin on the cell viability of malignant melanoma cells using an in vitro experiment to research alternative melanoma treatments and hopefully to help further cancer research as a whole.

One important factor that contributes to human cancers is accumulated damage to cells' DNA due to the oxidative stress caused by free radicals. In this study, the authors investigate the effects of several different tea leaf extracts on oxidative stress in cultured human prostate cells to see if antioxidants in the tea leaves could help protect cells from this type of DNA damage. They found that all four types of tea extract (as well as direct application of the antioxidant EGCG) improved the outcomes for the cultured cells, with white tea extract having the strongest effect. This research suggests that tea extracts and the antioxidants that they contain may have applications in the treatment of the many diseases associated with cellular DNA damage, including cancer.

Here, recognizing that the immune response to cancer results in biomarkers that can be used to assess the immune status of cancer patients, the authors investigated the concentrations of key cytokines (TH1 and TH2 cytokines) in healthy controls and cancer patients. They identified significant changes in resting and activated cytokine profiles, suggesting that data of biomarkers such as these could serve as a starting point for further treatment with regard to a patient's specific immune profile.

In this study, the authors identify new potential targets to treat advanced diffuse large B-cell lymphoma after treatment relapse and loss of CD19 expression.

Wang and Gong developed a novel dynamic gene-searching algorithm called Dynamic Gene Search (DyGS) to create a gene panel for each of the 12 cancers with the highest annual incidence and death rate. The 12 gene panels the DyGS algorithm selected used only 3.5% of the original gene mutation pool, while covering every patient sample. About 40% of each gene panel is druggable, which indicates that the DyGS-generated gene panels can be used for early cancer detection as well as therapeutic targets in treatment methods.

A significant percentage of cancer survivors develop a second primary cancer. Using data of deceased patients provided by the Peninsula Regional Medical Center, Li and Holdai conducted a retrospective statistical analysis to investigate whether the type of the first cancer affects the occurrence time and type of the second primary cancer.